Improvement effect of recombinant human erythropoietin on cognition disorders in acute brain infarction patients

Daihua Yu,Wei Li,Qian Yang,Xude Sun,Changjun Gao,Wei Chai

DOI: https://doi.org/10.3877/cma.j.issn.1674-6880.2017.02.004

2017-01-01

Abstract:Objective To study the improvement effect of recombinant human erythropoietin (rHu-EPO) on cognition disorders in acute brain infarction patients. Methods Acute brain infarction patients with cognition disorders were randomly divided into the control group (16 cases) and rHu-EPO group (18 cases), and two cases in each group were initiatively dropped out during the therapy. Patients in the control group received conventional treatment, and patients in the rHu-EPO group were given subcutaneous injection of 30 IU/kg rHu-EPO 3 times per week, and lasted for 4 weeks additionally. Montreal cognitive assessment scales (MoCA) were used to evaluate cognitive function, neural function defect were scaled according to the national institutes of health neurological deficit score (NIHSS) and infarction sizes were determined by magnetic resonance imaging before and after the therapy. Results Compared with before the therapy, the MOCA score (t=1.684, P=0.035; t=3.622, P=0.011), language function scores (t=2.258, P= 0.025; t=3.472, P=0.019) and delayed memory function scores (t=2.665, P=0.018; t=4.826, P=0.026) in the control group and rHu-EPO group all increased markedly, and the MoCA score [(20.21 ± 2.63) vs. (16.99 ± 2.28); t=4.183, P=0.011], language function scores [(2.76 ± 0.83) vs. (1.66 ± 0.71); t=4.865, P=0.008] and delayed memory function scores [(4.66 ± 1.38) vs. (3.12 ± 1.02); t = 2.643, P=0.025] in the rHu-EPO group were much higher than those in the control group. After the therapy, the NIHSS in the control group and rHu-EPO group were also lower than those before the therapy (t = 3.506, 8.126; P = 0.018, 0.002), and in the rHu-EPO group reduced obviously as compared with that in the control group (t=2.508, P=0.026). Meanwhile, the infarction sizes after the therapy only in the rHu-EPO group decreased as compared with before the therapy [(12.8 ± 3.5) cm3 vs. (8.2 ± 2.3) cm3; t=6.204, P=0.001], and in the rHu-EPO group were much smaller than those in the control group (t=3.268, P=0.022). Conclusion Based on conventional therapy, rHu-EPO may effectively improve cognition disorders in acute brain infarction patients, especially language and delayed memory function.